A
Alcista
Alcista · 25%AMED
$104.36
Precio del escenario
$100.990
+0.010 (+0.01%)Al cierre
Loading chart…
- Máximo
- 101.020
- Apertura
- 101.020
- Precio medio ponderado por volumen
- 100.98
- Volumen
- 1.06M
- Capitalización
- 3.04B
- Mínimo
- 100.930
- Importe
- 107.04M
- EV/EBITDA, TTM
- 12.17
Amedisys, Inc. is a healthcare services company. It provides in-home healthcare and related services to the chronic, co-morbid and aging American population. Its segments include home health, hospice and high acuity care. Its home health segment delivers a range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Its nurses administer medications, care for wounds, monitor vital signs and provide a range of other nursing services. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility care to patients in their homes. It owns and operates 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers and eight admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.
Recomendaciones de analistas (11)
+2.24% de potencial alcista
Mantener
5 Comprar
6 Mantener
0 Vender
Actual: 100.99
Mínimo
101.00
Promedio
103.25
Máximo
110.00
RBC Capital
Comprar
$100
2025-04-16
RBC Capital
2025-04-16
Precio objetivo
$100
Comprar
Stephens & Co.
Mantener
$101
2025-03-04
Stephens & Co.
2025-03-04
Precio objetivo
$101
Mantener
Stephens & Co.
Mantener
$101
2025-02-12
Stephens & Co.
2025-02-12
Precio objetivo
$101
Mantener
Deutsche Bank
Mantener
$101
2024-07-31
Deutsche Bank
2024-07-31
Precio objetivo
$101
Mantener
Cantor Fitzgerald
Mantener
$101
2024-07-25
Cantor Fitzgerald
2024-07-25
Precio objetivo
$101
Mantener
Métricas de valoración
El PER previsto actual de Amedisys Inc (AMED) es 18.61, frente a su media de 5 años de 21.56.
Escenarios de precio de Alphio AI para AMED
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
5.008-15BenzingaWhy Is UnitedHealth Stock Trading Higher Friday?
2.008-15SeekingAlphaTwilio set to join S&P MidCap 400
8.008-14BenzingaUnitedHealth Group Climbs 1.17% After Hours Following $2.21 Quarterly Dividend Authorization
8.508-11BenzingaWhat's Going On With UnitedHealth Stock Monday?
8.508-08BenzingaUnitedHealth Faces Large Outpatient Divestiture To Resolve Antitrust Suit Related To Amedisys Deal
Preguntas frecuentes sobre AMED, respondidas por Alphio AI
Amedisys, Inc. is a healthcare services company. It provides in-home healthcare and related services to the chronic, co-morbid and aging American population. Its segments include home health, hospice and high acuity care. Its home health segment delivers a range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Its nurses administer medications, care for wounds, monitor vital signs and provide a range of other nursing services. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility care to patients in their homes. It owns and operates 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers and eight admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).
11 analysts cover AMED: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 103.25.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.